India Biogeneric.........for double digit dollar revenue

One of the largest generic manufacturer of India Inc Cipla is planning to launch its own line of Bio similar products, in a press release Cipla's chairman Yusuf Hamied said that he plans to invest in companies in India and Hong Kong who will be able to produce so-called monoclonal antibodies. The technology will enable Mumbai-based Cipla to have access to products modelled bio equivalence to Roche’s Avastin, Herceptin cancer drugs and Amgen’s rheumatoid arthritis treatment Enbrel.

PS: Cipla is the largest supplier of HIV drugs:)

Link:http://www.businessweek.com/news/2010-06-16/cipla-targets-19-billion-a-year-roche-amgen-drugs-update2-.html